metaEvidence - overview


			deaths (OS)	progression or deaths (PFS)	RFS/DFS
mML - NA - all population metastatic/adv melanoma (mML) mML - (neo)adjuvant (NA) mML - NA - all population
mML - NA - PDL1 positive metastatic/adv melanoma (mML) mML - (neo)adjuvant (NA) mML - NA - PDL1 positive
mML - L1 - all population metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - all population
mML - L1 - BRAF mutant metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF mutant
versus placebo plus SoC
	atezolizumab plus SoC vs. placebo plus SoC	1	0.85 [0.65; 1.12], 1 RCT, I2=0% inconclusive result	0.78 [0.63; 0.97], 1 RCT, I2=0% unassessable degree of certainty	-
mML - L1 - BRAF wild metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF wild
versus pembrolizumab alone
	atezolizumab plus cometinib vs. pembrolizumab alone	1	1.06 [0.69; 1.62], 1 RCT, I2=0% inconclusive result	1.15 [0.88; 1.50], 1 RCT, I2=0% inconclusive result	-
mML - L2 - all population metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - all population
mML - L2 - BRAF mutant metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - BRAF mutant